Ocugen (OCGN) Return on Capital Employed (2015 - 2026)
Ocugen's (OCGN) quarterly Return on Capital Employed came in at 224.57% in Q1 2026, down 12373.0% YoY from N/an in Q1 2025, and up 1.8% on a QoQ basis from 228.68% in Q4 2025.
Ocugen (OCGN) Return on Capital Employed (2015 - 2026) Analysis & Trends
Ocugen (OCGN) has 12 years of Return on Capital Employed data on file, last reported at 224.57% in Q1 2026.
- Quarterly Return on Capital Employed fell 12373.0% year-over-year to 224.57% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 224.57% (down 12373.0% YoY) and the FY2025 annual result came in at 157.54%, down 5205.0% from the prior year.
- Return on Capital Employed advanced to 224.57% in Q1 2026, from 228.68% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 55.93% in Q2 2022 to a low of 228.68% in Q4 2025.
- A 5-year average of 132.0% and a median of 124.75% in 2023 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2025 — Return on Capital Employed soared 4811 bps — and 2026, when it plunged 12373 bps.
- Tracing OCGN's Return on Capital Employed over 5 years: stood at 106.16% in 2022, then fell by 18 bps to 124.75% in 2023, then climbed by 13 bps to 108.21% in 2024, then slumped by 111 bps to 228.68% in 2025, then gained by 2 bps to 224.57% in 2026.
- The last three Return on Capital Employed figures came in at 224.57% (Q1 2026), 228.68% (Q4 2025), and 169.61% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Ocugen | 457.71 Mn | 357.61 Mn | - | 162.03% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 162.03% |
| Mar 31, 2026 | -224.57% |
| Dec 31, 2025 | -228.68% |
| Sep 30, 2025 | -169.61% |
| Jun 30, 2025 | -134.97% |
| Mar 31, 2025 | -100.84% |
| Dec 31, 2024 | -108.21% |
| Sep 30, 2024 | -147.82% |
| Jun 30, 2024 | -183.08% |
| Mar 31, 2024 | -141.76% |
| Dec 31, 2023 | -124.75% |
| Sep 30, 2023 | -124.57% |
| Jun 30, 2023 | -132.14% |
| Mar 31, 2023 | -116.07% |
| Dec 31, 2022 | -106.16% |
| Sep 30, 2022 | -81.39% |
| Jun 30, 2022 | -55.93% |
| Mar 31, 2022 | -63.38% |
| Dec 31, 2021 | -55.78% |
| Sep 30, 2021 | -41.44% |